Evaluation of the comorbidity burden in patients with ankylosing spondylitis treated with tumour necrosis factor inhibitors using a large administrative claims data set.
Jessica A WalshXue SongGilwan KimYujin ParkPublished in: Journal of pharmaceutical health services research : an official journal of the Royal Pharmaceutical Society of Great Britain (2018)
Patients with AS treated with TNFis had higher incidence rates of IBD, uveitis and sleep apnoea after initiation of TNFi therapy than patients not treated with TNFi therapy.
Keyphrases
- ankylosing spondylitis
- newly diagnosed
- end stage renal disease
- rheumatoid arthritis
- ejection fraction
- chronic kidney disease
- disease activity
- prognostic factors
- peritoneal dialysis
- physical activity
- juvenile idiopathic arthritis
- stem cells
- health insurance
- obstructive sleep apnea
- systemic lupus erythematosus
- mesenchymal stem cells
- big data
- machine learning
- electronic health record
- patient reported outcomes
- sleep quality
- ulcerative colitis